Exhibit 99.1 Caribou Biosciences Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update -- 30th patient dosed in CB-010 ANTLER Phase 1 trial dose expansion; initial dose expansion data and RP2D to be disclosed in Q2 2024 -- -- 1st patient dosed in CB-012 AMpLify Phase 1 trial for patients with r/r AML -- -- $372.4 million in cash, cash equivalents, and marketable securities expected to fund the current operating plan into Q1 2026 -- BERKELEY, Calif., March 11, 2024 (GLOBE N ...